10 recruiting, 7 not yet recruiting, 4 completed, 4 terminated. 16 Phase 2, 12 Phase 1, 4 Phase 3, 2 Not applicable.
Follow Advanced Hepatocellular Carcinoma (HCC): new trials by email Literature Review of Advanced Hepatocellular Carcinoma (HCC) trials Research Report on Advanced Hepatocellular Carcinoma (HCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma Ivonescimab - Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | MedSIR | 44 | 2027-03-01 | 2026-11-04 |
| Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC FMT combined with QL1706 plus Bevacizumab - Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 20 | 2026-10-10 | 2026-10-08 |
| A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC WGI-0301, Lenvatinb - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang Haichang Biotech Co., Ltd. | 80 | 2026-09-01 | 2026-09-15 |
| Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy - NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | BOE Technology Group Co., Ltd. | 42 | 2026-08-01 | 2026-08-26 |
| An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma Super CAR-T - Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma | Phase 1 | Recruiting | Guangzhou FineImmune Biotechnology Co., LTD. | 15 | 2026-03-27 | 2026-05-14 |
| Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide - Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-03-30 |
| Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes Advanced Hepatocellular Carcinoma (HCC) | Not yet recruiting | Ahmed Karam Helmy | 75 | 2026-01-01 | 2026-01-06 | |
| Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer HA131, Enlonstobart Injection, Pembrolizumab Injection - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 116 | 2025-12-23 | 2025-12-15 |
| Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment Sintilimab, Bevacizumab Biosimilar, Camrelizumab - Advanced Hepatocellular Carcinoma (HCC) | Recruiting | Fudan University | 150 | 2025-09-01 | 2026-04-21 | |
| Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine, iNeo-Vac-T01 Personalized T Cell Injection - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Recruiting | Zhejiang University | 20 | 2025-08-01 | 2025-08-14 |
| A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma Super Hi-TCR-T cells - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Recruiting | Eastern Hepatobiliary Surgery Hospital | 30 | 2025-07-30 | 2025-09-03 |
| A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) CG-102-12C - Advanced Hepatocellular Carcinoma (HCC) | Not applicable | Recruiting | Zhejiang University | 12 | 2025-06-28 | 2026-01-22 |
| A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion Particle beam radiation therapy - Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | National Cancer Center, Korea | 128 | 2025-04-15 | 2025-12-26 |
| Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma TACE, Sintilimab combined with Bevacizumab, individualized anti-tumor new antigen iNeo-Vac-R01 injection - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Recruiting | Zhejiang University | 30 | 2025-04-09 | 2025-05-29 |
| HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma HAI Adebrelimab, intravenous infusion (IV) of Adebrelimab (ADE), intravenous infusion (IV) of Bevacizumab (Bev.) - Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Sun Yat-sen University | 76 | 2025-01-03 | 2026-09-25 |
| Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma Prehabilitation, Routine nursing measures - Advanced Hepatocellular Carcinoma (HCC), Prehabilitation | Not applicable | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 84 | 2025-01-01 | 2024-12-27 |
| Phase 2 Study of WGI-0301 for Advanced HCC WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously - Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Zhejiang Haichang Biotech Co., Ltd. | 60 | 2024-07-31 | 2026-09-11 |
| The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma DEB-TACE plus HAIC or HAIC alone - Advanced Hepatocellular Carcinoma (HCC) | Unknown | Peking University Cancer Hospital & Institute | 200 | 2023-01-01 | 2023-05-22 | |
| A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) CDK-004 - Advanced Hepatocellular Carcinoma (HCC), Gastric Cancer Metastatic to Liver | Phase 1 | Terminated | Codiak BioSciences | 9 | 2022-06-28 | 2023-06-01 |
| A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) camrelizumab；Rivoceranib, Rivoceranib, Sorafenib - Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 1 | 2021-09-26 | 2022-09-01 |
Showing 20 of 29. Sign in to see all of them.
Carcinoma, Hepatocellular (3) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Liver Neoplasms (1) · Simpson-Golabi-Behmel syndrome (1)
Digestive System Diseases (5) · Digestive System Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Liver Diseases (4) · Adenocarcinoma (3) · Carcinoma (3) · Liver Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
Bevacizumab (6) · Sorafenib (4) · apatinib (2) · lenvatinib (2) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1) · Axitinib (1) · BID protein, human (1) · Capecitabine (1) · Cetuximab (1) · Cyclophosphamide (1) · Folfox protocol (1) · Genes, p53 (1) · Infusions, Intravenous (1) · Ipilimumab (1) · LY-2157299 (1)
Shanghai Junshi Bioscience Co., Ltd. (3) · Zhejiang University (3) · Zhejiang Haichang Biotech Co., Ltd. (2) · Abramson Cancer Center at Penn Medicine (1) · Ahmed Karam Helmy (1) · Astellas Pharma Inc (1) · BOE Technology Group Co., Ltd. (1) · Beijing Biotech (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Codiak BioSciences (1) · Eastern Hepatobiliary Surgery Hospital (1) · Fudan University (1) · Guangzhou FineImmune Biotechnology Co., LTD. (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
China (19) · United States (4) · Singapore (3) · Hong Kong (2) · Italy (2) · South Korea (2) · Taiwan (2) · Belgium (1) · Egypt (1) · France (1) · Germany (1) · Poland (1) · Spain (1) · Ukraine (1)
Gerald Prager, MD (1) · Hao Jihui, MD, PhD (1) · Kim Reiss Binder, MD (1) · Zhang Ningning, MD, PhD (1) · ZhengGang Ren, PhD (1)